The Claim
Recombinant human TSH induces a strong cyclic AMP response in differentiated orbital fibroblasts from patients with Graves' ophthalmopathy but does not significantly increase hyaluronan synthesis in 11 out of 12 tested cultures.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In cells taken from patients with Graves' ophthalmopathy, recombinant human TSH triggers a strong increase in cyclic AMP but does not cause a significant rise in hyaluronan synthesis in most cell cultures.
See the scientific wording
Recombinant human TSH induces a strong cyclic AMP response in differentiated orbital fibroblasts from patients with Graves' ophthalmopathy but fails to significantly increase hyaluronan synthesis in all but one of 12 tested cultures.
When the TSH hormone binds to its receptor on fat-like cells in the eye socket, it turns on a chemical signal called cAMP, but this signal does not turn on the production of the gooey substance that causes swelling. Only a different type of antibody, not the hormone, can turn on that swelling substance.
What the research says
1 studyIn cells from people with Graves' eye disease, the hormone TSH makes a chemical called cAMP go up, but it usually doesn't make the gooey substance (hyaluronan) that causes swelling. So TSH triggers one signal but not the other.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.